- ISIN
- US98943L1070
- CUSIP
- 98943L107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 3, 2020
Highlights
- Market Cap
- $257.87M
- Enterprise Value
- $260.59M
- EPS (TTM)
- -$1.74
- Gross Profit (TTM)
- -$157.00K
- EBITDA (TTM)
- -$136.37M
- Year Range
- $1.13 - $6.95
- Target Price
- $10.00
- ROA (TTM)
- -49.05%
- ROE (TTM)
- -67.95%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ZNTL Performance Chart
Zentalis Pharmaceuticals, Inc. (ZNTL) is up 171.9% since the beginning of the year. At $4 per share, ZNTL is trading 47.2% below its 52-week high of $7. Investors who bought $1,000 worth of ZNTL shares 5 years ago would now be looking at an investment worth $70.
Loading charts...
Returns By Period
Zentalis Pharmaceuticals, Inc. (ZNTL) has returned 171.85% so far this year and 182.31% over the past 12 months.
Zentalis Pharmaceuticals, Inc.
- 1D
- -0.81%
- 1M
- -9.61%
- YTD
- 171.85%
- 6M
- 162.14%
- 1Y
- 182.31%
- 3Y*
- -49.79%
- 5Y*
- -41.23%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ZNTL Monthly Returns History
Based on dividend-adjusted daily data since Apr 3, 2020, ZNTL's average daily return is +0.04%, while the average monthly return is +0.39%. At this rate, an investment would double in approximately 14.8 years.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2026 with a return of +80.0%, while the worst month was Jun 2024 at -65.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ZNTL closed higher 48% of trading days. The best single day was Apr 9, 2026 with a return of +60.1%, while the worst single day was Jun 18, 2024 at -50.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 80.00% | -1.65% | -2.09% | 71.37% | -0.25% | -8.25% | 171.85% | ||||||
| 2025 | -42.57% | 18.97% | -23.19% | -10.69% | -14.79% | -4.13% | 18.97% | 22.46% | -10.65% | -0.66% | -4.67% | -5.59% | -55.45% |
| 2024 | -21.78% | 25.82% | 5.70% | -29.82% | 7.41% | -65.57% | -4.89% | -10.80% | 6.05% | -25.82% | 32.23% | -16.07% | -80.00% |
| 2023 | 17.18% | -19.79% | -9.14% | 28.08% | 18.20% | 8.33% | -5.32% | -0.56% | -24.47% | -18.44% | -31.23% | 34.67% | -24.78% |
| 2022 | -32.10% | -12.60% | -7.52% | -42.52% | -9.09% | 16.55% | 3.91% | -8.18% | -19.21% | 15.84% | -11.84% | -8.95% | -76.04% |
| 2021 | -26.13% | 9.56% | 3.21% | 36.71% | -5.85% | -4.74% | 0.02% | 28.15% | -2.27% | 20.71% | 2.00% | 2.45% | 61.84% |
Benchmark Metrics
Zentalis Pharmaceuticals, Inc. has an annualized alpha of -17.58%, beta of 1.55, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since April 03, 2020.
- This stock participated in 222.14% of S&P 500 Index downside but only 67.25% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -17.58%
- Beta
- 1.55
- R²
- 0.09
- Upside Capture
- 67.25%
- Downside Capture
- 222.14%
Return for Risk
Risk / Return Rank
ZNTL ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Zentalis Pharmaceuticals, Inc. (ZNTL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZNTL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.57 | ||
| Sortino ratioReturn per unit of downside risk | +0.20 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.37 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 3.92 | 2.78 | +1.14 |
| Martin ratioReturn relative to average drawdown | 6.54 | 12.44 | -5.90 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Zentalis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Zentalis Pharmaceuticals, Inc. was 98.77%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Zentalis Pharmaceuticals, Inc. drawdown is 95.67%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -98.77%Apr 2025 | 3y 5mo | — | 4y 7moNov 2021 - now |
2020 bear market2020 | -50.68%Sep 2020 | 2mo 10d | 3mo 5d | 5mo 15dJun 2020 - Dec 2020 |
2021 bear market2021 | -38.43%Feb 2021 | 2mo 11d | 2mo 4d | 4mo 15dDec 2020 - Apr 2021 |
2021 bear market2021 | -24.77%Jul 2021 | 2mo 10d | 1mo 20d | 4moApr 2021 - Aug 2021 |
2020 bear market2020 | -21.35%Jun 2020 | 10d | 6d | 16dJun 2020 - Jun 2020 |
Drawdown Indicators
| ZNTL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.77% | -56.78% | -41.99% |
Max Drawdown (1Y)Largest decline over 1 year | -46.75% | -9.10% | -37.65% |
Max Drawdown (3Y)Largest decline over 3 years | -96.41% | -18.90% | -77.51% |
Max Drawdown (5Y)Largest decline over 5 years | -98.77% | -25.43% | -73.34% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -95.67% | -1.80% | -93.87% |
Average DrawdownAverage peak-to-trough decline | -64.32% | -10.71% | -53.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.01% | 2.03% | +25.98% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Zentalis Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Zentalis Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ZNTL in comparison with other companies in the Biotechnology industry. Currently, ZNTL has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ZNTL
Add Zentalis Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ZNTL